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Objectives: Primary small cell carcinoma of the endometrium is a rare disease that can only be diagnosed
at an advanced stage, and thus has a poor prognosis. In this study, the clinicopathologic characteristics of
endometrial small cell carcinoma are described and the survival outcomes are discussed.
Materials and methods: The data from six patients from a single medical institution who were diagnosed
with endometrial small cell carcinoma in the past 20 years were retrospectively reviewed.
Results: The median age of the six patients was 60 years. Vaginal bleeding was the most common
symptom. All six patients underwent complete staging surgery, including hysterectomy, bilateral sal-
pingoophorectomy, and systematic lymphadenectomy. Three of the patients were diagnosed with early
stage disease, [International Federation of Gynecology and Obstetrics (FIGO) stage I or II], and the other
three were in an advanced stage (FIGO stage III). Pathologically, deep myometrial invasion was observed
in ﬁve (83.3%) of the patients, and lymphovascular invasion in six. As adjuvant therapy, four (66.7%)
patients received platinum-based chemotherapy and one (16.7%) underwent concurrent chemo-
radiotherapy. During the median follow-up period of 16.2 months, recurrence developed in four patients
(66.7%). There were disseminated recurrences on the peritoneum and lymph nodes in two cases, and
distant metastasis to the brain in the other two cases. The median time to recurrence was 7.5 months
(range, 315 months). One patient died of disease.
Conclusion: Small cell carcinoma of the endometrium shows an aggressive clinical behavior, such as a
disseminated disease and distant metastasis within a short time to recurrence. Initial active management
with complete surgical resection and systemic chemotherapy might improve outcomes, although further
large studies should be done to conﬁrm this.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Small cell carcinomas can occur in almost any organ, although
they are usually seen in the lung, and less frequently in the
gastrointestinal and genitourinary tracts. In the female genital tract,
the cervix is the most common site for carcinomas, accounting for
2% of cervical cancers. The endometrium is the least common site,
representing only 0.8% of all endometrial cancers [1]. Since Albores-
Saavedra et al [2] ﬁrst described endometrial small cell carcinomand Gynecology, University of
1, Pungnap-dong, Songpa-gu,
bstetrics & Gynecology. Publishedin 1979, more than 80 cases have been reported in the English-
language medical literature. The clinical and biological character-
istics are usually described as being similar to those of endometrial
adenocarcinomas [3], although the disease prognosis in endome-
trial small cell carcinoma is usually extremely poor.
In a review of the literature, two thirds of patients with
follow-up observation of at least 1 year usually died within the
year, and recurrences developed in a majority of the remaining
patients [4]. Disseminated disease with early involvement of the
lymph nodes and other distant organs is also commonly
observed. To date, 60% of the cases reported had advanced In-
ternational Federation of Gynecology and Obstetrics (FIGO) stage
III or IV, and the median survival was reported to be only 5
months [5]. Nevertheless, unlike endometrial adenocarcinoma,
an optimal treatment has not yet been well deﬁned due to theby Elsevier Taiwan LLC. All rights reserved.
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cases of endometrial small cell carcinoma conﬁrmed by surgery.
The aim of the present study is to investigate the clinicopatho-
logic features of endometrial small cell carcinoma, and review its
management and survival outcomes.
Materials and methods
Patients with endometrial small cell carcinoma surgically
diagnosed between January, 1989 and December, 2011 at Asan
Medical Center, Seoul, Korea, were retrospectively identiﬁed ac-
cording to their pathology reports. Cases that were eligible for
enrollment in this study met the diagnostic criteria proposed by
Van Hoeven et al [6] as follows: (1) unequivocal evidence of
endometrial origin; (2) dense, sheet-like growth of morphologi-
cally similar, small- to intermediate-sized tumor cells in standard
hematoxylin and eosin-stained sections; and (3) immunohisto-
chemical staining for one or more neuroendocrine markers. Pa-
tients with other coexisting pathologies were also included.
All pathology slides were conﬁrmed by a clinically experi-
enced pathologist. In each case, hematoxylineosin-stained sec-
tions were available for review. To conﬁrm the diagnosis,
immunohistochemical staining for chromogranin and synapto-
physin, estrogen receptor (ER), and progesterone receptor (PR)
were performed on formalin-ﬁxed, parafﬁn-embedded tissue
sections using a Benchmark automatic immunostaining device
(Ventana Medical Systems Inc., Tucson, AZ, USA). Brieﬂy, 5-mm
sections were transferred onto adhesive slides and dried at 62C
for 30 minutes. After standard, heat-mediated epitope retrieval
for 30 minutes in EDTA (pH 8.0) in an autostainer, the samples
were incubated with antibodies to chromogranin (1:200, Dako
Cytomation, Carpinteria, CA, USA), synaptophysin (1:100, Neo-
marker, Fremont, CA, USA), ER (1:50; Novocastra Laboratories,
Newcastle, UK), and PR (1:200; Novocastra Laboratories, New-
castle, UK). The sections were subsequently incubated with bio-
tinylated, antimouse immunoglobulins, peroxidase-labeled
streptavidin (LSAB kit, DAKO, Glostrup, Denmark), and 3,30-
diaminobenzidine. Normal breast tissue was used as a positive
control for ER and PR, and normal adrenal gland for both chro-
mogranin and synaptophysin, and negative control samples
omitted the primary antibody.
Based on our institutional policy, uteri were sent to the pa-
thology laboratory for frozen sectioning immediately after hys-
terectomy in cases of endometrial cancer. After conﬁrming the
histology type and invasion state on the frozen sections, it was
decided the extent of debulking surgery that should be per-
formed. In cases undergoing adjuvant chemotherapy, serum
CA125 level is routinely measured prior to every cycle of
chemotherapy, and positron emission tomography (PET) or PET/
computerized tomography (CT) imaging is used every three cy-
cles of chemotherapy to estimate disease progression. As part of
routine posttherapy surveillance, clinical examinations and
CA125 level checks are performed every 3 months for 2 years and
every 3e6 months for the following 3 years. A PET or PET/CT scan
is usually performed 3 months after completing the initial
treatment, and every 612 months for the next 5 years or when
clinically indicated.
Patients' medical records were reviewed for demographic
characteristics, surgical ﬁndings, and clinical progression during
follow-up. Preoperative information was analyzed, including pa-
tient's age, obstetric history, body mass index, initial CA 125 level,
presenting symptoms, and tumor size on imaging workup, as
well as postoperative data, including surgical procedures, tumor
stage, immunohistochemical staining, modality of adjuvant
treatment, and survival outcomes. The tumors were stagedaccording to the 2009 FIGO staging system for carcinomas of the
endometrium.
Results
Over the 20 years of the study, six cases of endometrial small cell
carcinoma were identiﬁed out of a total of 1373 endometrial can-
cers, accounting for 0.44% of tumors. This rate was lower than the
rate of cervical small cell carcinomas (1.5%) detected at the Asan
Medical Center. In six cases, the tumor was mainly observed in the
endometrium, and neither in the cervix nor the adnexa (Fig. 1A).
As shown in Table 1, the median age of these patients was 60
years (range 5268 years), and the median parity was 2.3 (range 05).
All patients presented vaginal bleeding, and four (66.7%) patients
received a dilation and curettage, which conﬁrmed endometrial
malignant tumor. Among the remaining two patients, one under-
went surgery with preoperative diagnosis of endometrial myoma
or polyp (Patient 1), and the other received ultrasound and mag-
netic resonance imaging (MRI) but no endometrial biopsy because
she had no sexual history (Patient 4). The median diameter of
endometrial tumor was 7.3 cm (range, 3.213 cm) on preoperative
imaging. None of the patients had a preoperative increase in either
of the tumor markers CA-125 (>35 U/mL) or SCC-Ag (>0.5 ng/mL),
except one patient who showed elevated CA-125 (75.4 U/mL; Pa-
tient 5).
At the beginning of the staging surgery, uteri were sent to the
pathology laboratory for frozen sectioning, which conﬁrmed
endometrial small cell carcinoma in all cases. Complete staging
surgery, including hysterectomy, bilateral salpingoophorectomy,
and pelvic and para-aortic lymphadenectomy with or without
omentectomy, was performed for all patients. The abdominal
approach for hysterectomy was performed for four (66.7%) pa-
tients, and laparoscopic surgery was performed in two (33.3%)
patients. There were no residual tumor masses in any cases. None
of the patients had evidence of distant metastasis or indications of
FIGO stage IV at the time of their diagnosis. Half the patients (three
cases) had early stage (FIGO IA, IB, and II) disease, and the other
half (three patients) had advanced stage (FIGO IIIB, IIIC1, and
IIIC2).
Pathologically, pure small cell carcinoma was only seen in two
patients (33.3%). The remaining four patients (66.7%) had combined
small cell carcinoma with other pathologies, such as endometrioid
adenocarcinoma, endocervical adenocarcinoma in situ, or endo-
cervical polyp (Table 2). Lymphovascular invasion was observed in
all cases (Fig. 1B), but only two patients (33.3%) had metastatic
lymph nodes.
With the exception of one patient who refused adjuvant treat-
ment, ﬁve patients (83.3%) underwent platinum-based chemo-
therapy or concurrent chemoradiation therapy following surgery,
but recurrence developed as disseminated disease or as distant
metastasis in four patients (66.7%). The median time to recurrence
after surgery was 7.5 months (range, 315 months). One patient died
of disease during the median follow-up period of 16.2 months.
However, four patients (66.7%) have remained alive for more than 1
year after their ﬁrst surgery. One of them has no evidence of disease
(Patient 1) and another two are in a state of progressive disease
(Patients 3 and 5). In the other patient (Patient 4), the disease state
is unclear because she refused to be examined by either a physician
or an imaging modality.
In all the recurrent cases, recurrence was ﬁrst detected by the
patient's symptoms, and not by abnormal ﬁndings on imaging or
elevated CA 125. Only one patient showed elevated CA 125 (50.5 U/
mL in Patient 6) when disease recurrence was found. The symp-
toms were decreased sensation on the right side of the face in
Patient 1, hematuria in Patient 3, weakness in the right leg in
Fig. 1. (A) Macroscopic appearance of the surgical specimen in case 1 with stage IA. The arrow points to a tumor of the endometrium measuring 3.5 cm  2.5 cm  1 cm and
inﬁltrating the superﬁcial myometrium. (B) A magniﬁcation of the uterine wall. Small cell neuroendocrine carcinoma shows frequent tumor emboli within the lymphovascular
spaces in the myometrium (hematoxylin & eosin,  40). (C) Small cell neuroendocrine carcinoma cells have hyperchromatic nuclei with ﬁnely stippled chromatin, inconspicuous
nucleoli, and high nuclear to cytoplasmic ratios (hematoxylin & eosin,  400). (D) Microscopic features of the small cell neuroendocrine carcinoma. The tumor is composed of
variable sized sheets, nests, and cords of closely packed, small cells with geographic necrosis (hematoxylin & eosin,  40). (EeH) Immunohistochemistry stains of the small cell
carcinoma are positive for synaptophysin (E), chromogranin (F), CD 56 (G), and neuron-speciﬁc enolase (H) (original magniﬁcation  100).
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suggested that monitoring serum CA 125 and SCC levels are not
useful for follow-up in endometrial small cell carcinoma.
Microscopic and immunohistological features
On microscopic examination, tumors were characterized by a
monotonous proliferation of small round cells with hyperchromaticand irregularly shaped nuclei, indistinct nucleoli, and a small
amount of cytoplasmwith a high nucleus/cytoplasm ratio (Fig. 1C).
Numerous mitotic ﬁgures were noted (up to 30 per 10 high-power
ﬁelds). Rosette formation was not prominent, and extensive tumor
necrosis was found in three cases (Fig. 1D).
An immunohistochemical study of the specimens yielded pos-
itive reactions for synaptophysin in six patients (100%) and chro-
mogranin in three patients (50%) among the patients who were
Table 1
The demographic characteristics of six patients with small-cell endometrial carcinoma.
Pt. 1 Pt. 2 Pt. 3 Pt. 4 Pt. 5 Pt. 6
Age (y) 52 63 68 52 68 55
Gravidity 3 35 6 0 5 3
Parity 2 5 3 0 2 2
Menopause Yes Yes Yes No Yes No
BMI (kg/m2) 22.5 24.3 21.5 21.5 28.4 18.3
CA 125 (U/mL) NA 13.9 10.2 29.3 75.4 7.8
Symptoms Vaginal bleeding Vaginal bleeding Vaginal bleeding Vaginal bleeding Vaginal bleeding Vaginal bleeding
D&C result Not performed Malignant tumor
of unspeciﬁed type
Endometrioid adenoca.
with small cell ca.
Not performed Extensive necrosis
with atypical cell clusters
Small cell
neuroendocrine ca
Tumor size (cm) 3.5 6.8 3.2 13 9 8
Hysterectomy type LAVH TAH LRH TAH TAH TAH
FIGO stage IA IB II IIIB IIIC1 IIIC2
BMI ¼ body mass index; D&C ¼ dilatation and curettage; LAVH ¼ laparoscopic-assisted vaginal hysterectomy; LRH ¼ laparoscopic radical hysterectomy; NA ¼ not available;
Pt. ¼ patient; TAH ¼ total abdominal hysterectomy.
Table 2
Pathologic results and clinical outcomes.
Pt. 1 Pt. 2 Pt. 3 Pt .4 Pt. 5 Pt.6
LVSI Yes Yes Yes Yes Yes Yes
Combined pathology Endometrioid
adnoca. (20%), CHA
Endometrioid
adnoca. (10%), CHA
Endocervical ACIS Endocervical polyp
PLN retrieved (n) 25 30 42 28 55 41
PALN retrieved (n) 3 4 22 12 21 20
PLNM No No No No Yes Yes
PALNM No No No No No Yes
Neoadjvant treatment No No No No No 3 cycles EP
Initial adjuvant treatment 6 cycles TP 6 cycles EP 6 cycles EP No CCRT with 6 cycles cisplatin 5 cycles TP
Recurrence Yes No Yes NA Yes Yes
CA 125 level at recurrence 3.7 22.1 54.8 50.5
Recurrent site Brain Lung, liver, pelvic
wall, bladder, PLN
Brain Peritoneal seeding, PALN
Time to recurrence (mo) 9 15 3 3
Postrecurrent treatment GKRS, 6 cycles EP None GKRS, 6 cycles TP None
OS (mo) 15 5 19 25 29 4
Current state NED NED AWD AWD AWD DOD
ACIS ¼ adenocarcinoma in situ; AWD ¼ alive with disease; CCRT ¼ concurrent chemoradiotherapy; CHA ¼ complex hyperplasia with atypia; DOD ¼ died of disease;
EP ¼ etoposide/cisplatin; GKRS ¼ gamma knife radiosurgery; LVSI ¼ lymphvascular space invasion; NA ¼ not available; NED ¼ no evidence of disease; OS ¼ overall survival;
PALN ¼ paraaortic lymph node; PLN ¼ pelvic lymph node; TP ¼ paclitaxel/cisplatin; Pt. ¼ patient.
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in three patients, whereas ER and PR were only positive in the
combined endometrioid adenocarcinoma components (Table 3).Discussion
In the present study, the clinicopathologic characteristics of
primary small cell carcinoma of the endometrium are described
and management of six cases and the clinical outcomesTable 3
Immunohistochemical staining in six patients.
Pt. 1 Pt. 2 Pt. 3 Pt. 4 Pt. 5 Pt. 6
Synaptophysin þ þ Strong þ Diffuse
strong þ
þ þ
CD56 þ NA NA NA Focal þ þ
NSE NA NA NA NA þ NA
Chromogranin   Focal þ Diffuse
strong þ
 þ
P16 NA Focal þ
(<10%)
þ NA 
þ
ER Focal strong þ Focal þ NA   
PR Focal strong þ  NA   
ER ¼ estrogen receptor; NA ¼ not available; NSE ¼ neuron-speciﬁc enolase;
PR ¼ progesterone receptor; Pt. ¼ patient.experienced are presented. Despite aggressive surgery with adju-
vant treatment, recurrence was commonly observed, involving
disseminated disease and distant metastasis.
The tumors showed distinctive cytologic features consisting of
small uniform cells in sheets, nests, and trabeculae with hyper-
chromatic nuclei and scanty cytoplasm. They had a high nuclear to
cytoplasmic ratio and a characteristic chromatin pattern. Immu-
nohistochemical staining was helpful in differential diagnosis from
poorly differentiated endometrial carcinoma, stromal sarcoma,
mixed mesodermal tumor, or primitive neuro-ectodermal tumors
of the uterus [7].
The clinical characteristics of endometrial small cell carcinoma
have been fairly well described in the medical literature, including
three large series with 16, 10, and 16 cases each [1,6,8]. The average
patient age at the time of diagnosis has been reported to be 60 years
old, which is 10 years older than the age for endometrial adeno-
carcinoma [9]. Endometrial small cell carcinoma, a rare neuroen-
docrine tumor, tends to develop in womenwith parity greater than
two and presents with vaginal bleeding as the most common
symptom. Most of these tumors are huge, bulky, and have deep
myometrial invasion at the time of diagnosis; lymphovascular in-
vasion is also observed in approximately 70% of these cases [1].
These previous ﬁndings agree with those of our current study.
Small cell carcinoma of the endometrium is aggressive and
highly malignant in its clinical behavior. Advanced stage is
commonly observed at diagnosis. To date, about 83 cases of
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literature; 40.8% (29 of 71 patients) were FIGO stage I or II and 59.2%
(42 of 71 patients) were stage III or IV among the cases with
available staging data [3,10e12]. Huntsman et al [1] published the
largest study to date, with 16 cases of small cell carcinoma of the
endometrium, among which ~53% of their cases were stage III or
higher and 33% were stage IVB, which includes distant metastasis.
Similarly, early stage (FIGO I or II) was seen in only half of the pa-
tients in the present study.
In most of the small published case series, the 5-year survival
rate varied from 17% to 64%, with a median survival between 12
months and 21 months [1,4,13]. The FIGO stage of the disease is the
most important prognostic factor [3]. In a literature review, Kata-
hira et al [9] found that only 23% (3/13) of the patients with stage I
disease died of the disease within 5 years. By contrast, 73% (17/22)
of patients with stages IIeIV disease died within 2 years of diag-
nosis. In addition, Korcum et al [3] reviewed 19 cases of stage I
disease comprising their one case and 18 previously reported cases.
There were 13 (68.4%) patients with no evidence of disease at the
time of follow-up, and four (21.1%) long-term survivors with no
evidence of disease after 5 years. More recently, Matsumoto et al [5]
published a review of long-term survivors of >1 year who had been
evaluated in previous reports. Of 53 patients with detailed infor-
mation available, 20 (37.7%) patients were long-term survivors; 17
(85%) of these 20 patients had stage I or II disease, and only three
(15%) had stage III or IV disease. In this study, four (66.7%) of six
patients survived >1 year after surgery, and two of these four cases
had advanced stage IIIB or IIIC disease. Although it is difﬁcult to
determine the exact factors affecting recurrence and survival out-
comes due to this sample size, we believe that the aggressive sur-
gical resection of tumor mass and adjuvant chemotherapy with or
without radiotherapy appeared to be responsible for the positive
outcomes in our population.
Even though there has been only limited data to conﬁrm the
optimal management strategies, it is generally accepted that sur-
gery is the cornerstone of treatment. In cases of advanced stage
disease, adjuvant radiotherapy and chemotherapy can be used
either alone or in combination, which is similar to the therapies
used for endometrial carcinoma. Several researchers have stated
that adjuvant therapy is alsowarranted in early stage disease on the
basis of the aggressive behavior of small cell carcinomas of the
endometrium [1,3,14]. According to their literature review, Korcum
et al [3] suggested that brachytherapy for loco-regional control may
be adequate with the addition of cisplatin to prevent systemic
micrometastasis, followed by cisplatin and etoposide chemo-
therapy for stage IB disease. However, small cell carcinomas of the
endometrium frequently show disseminated disease, including
para-aortic lymph node involvement and distant metastasis [1], in
contrast to endometrial adenocarcinomas, which mostly recur in
the vagina. With this in mind, radical surgery with adjuvantchemotherapy would be appropriate for both early- and advanced-
stage disease.
In summary, experience with endometrial small cell carcinoma
is detailed, which frequently shows disseminated disease or distant
metastasis at the time of recurrence in both early and advanced
stage disease. The median time to recurrence was as short as 7.5
months despite optimal treatment by surgery with adjuvant
chemotherapy or chemoradiation therapy. Although the small
number of patients in this study precludes drawing deﬁnite treat-
ment guidelines, it is suggested that clinicians should fully counsel
poor prognosis and take multimodal treatment into account. It will
be necessary to collect international information and experience
focused on the early detection of disease recurrence as well as the
optimal management strategy.Conﬂicts of interest
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